A Systematic Comparative Assessment of the Response of Ovarian Cancer Cells to the Chemotherapeutic Cisplatin in 3D Models of Various Structural and Biochemical Configurations-Does One Model Type Fit All?

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Mar 10

PMID 35267582

Authors

Priyanka Gupta

Aline Miller

Adedamola Olayanju

Thumuluru Kavitha Madhuri

Eirini Velliou

Affiliations

Soon will be listed here.

Abstract

Epithelial Ovarian Cancer (EOC) is a silent, deadly and aggressive gynaecological disease with a relatively low survival rate. This has been attributed, to some extent, to EOC's high recurrence rate and resistance to currently available platinum-based chemotherapeutic treatment methods. Multiple groups have studied and reported the effect of chemotherapeutic agents on various EOC 3D in vitro models. However, there are very few studies wherein a direct comparative study has been carried out between the different in vitro 3D models of EOC and the effect of chemotherapy within them. Herein, we report, for the first time, a direct comprehensive systematic comparative study of three different 3D in vitro platforms, namely (i) spheroids, (ii) synthetic PeptiGels/hydrogels of various chemical configurations and (iii) polymeric scaffolds with coatings of various extracellular matrices (ECMs) on the cell growth and response to the chemotherapeutic (Cisplatin) for ovary-derived (A2780) and metastatic (SK-OV-3) EOC cell lines. We report that all three 3D models are able to support the growth of EOC, but for different time periods (varying from 7 days to 4 weeks). We have also reported that chemoresistance to Cisplatin, in vitro, observed especially for metastatic EOC cells, is platform-dependent, in terms of both the structural and biochemical composition of the model/platform. Our study highlights the importance of selecting an appropriate 3D platform for in vitro tumour model development. We have demonstrated that the selection of the best platform for producing in vitro tumour models depends on the cancer/cell type, the experimental time period and the application for which the model is intended.

Citing Articles

3D tumor spheroids: morphological alterations a yardstick to anti-cancer drug response.

Senrung A, Lalwani S, Janjua D, Tripathi T, Kaur J, Ghuratia N In Vitro Model. 2025; 2(6):219-248.

PMID: 39872501 PMC: 11756486. DOI: 10.1007/s44164-023-00059-8.

Advanced tumor organoid bioprinting strategy for oncology research.

Cui X, Jiao J, Yang L, Wang Y, Jiang W, Yu T Mater Today Bio. 2024; 28:101198.

PMID: 39205873 PMC: 11357813. DOI: 10.1016/j.mtbio.2024.101198.

Double Imprinted Nanoparticles for Sequential Membrane-to-Nuclear Drug Delivery.

Singla P, Broughton T, Sullivan M, Garg S, Berlinguer-Palmini R, Gupta P Adv Sci (Weinh). 2024; 11(36):e2309976.

PMID: 38973256 PMC: 11423068. DOI: 10.1002/advs.202309976.

Microphysiological systems as models for immunologically 'cold' tumors.

Gaebler D, Hachey S, Hughes C Front Cell Dev Biol. 2024; 12:1389012.

PMID: 38711620 PMC: 11070549. DOI: 10.3389/fcell.2024.1389012.

Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer.

Abujamous L, Soltani A, Al-Thawadi H, Agouni A Biomol Biomed. 2024; 24(2):230-237.

PMID: 38231530 PMC: 10950340. DOI: 10.17305/bb.2023.9757.

References

Hedegaard C, Redondo-Gomez C, Tan B, Ng K, Loessner D, Mata A . Peptide-protein coassembling matrices as a biomimetic 3D model of ovarian cancer. Sci Adv. 2020; 6(40). PMC: 7852381. DOI: 10.1126/sciadv.abb3298. View

Lal-Nag M, McGee L, Titus S, Brimacombe K, Michael S, Sittampalam G . Exploring Drug Dosing Regimens In Vitro Using Real-Time 3D Spheroid Tumor Growth Assays. SLAS Discov. 2017; 22(5):537-546. DOI: 10.1177/2472555217698818. View

Lachowski D, Matellan C, Cortes E, Saiani A, Miller A, Del Rio Hernandez A . Self-Assembling Polypeptide Hydrogels as a Platform to Recapitulate the Tumor Microenvironment. Cancers (Basel). 2021; 13(13). PMC: 8267709. DOI: 10.3390/cancers13133286. View

Gunay G, Kirit H, Kamatar A, Baghdasaryan O, Hamsici S, Acar H . The effects of size and shape of the ovarian cancer spheroids on the drug resistance and migration. Gynecol Oncol. 2020; 159(2):563-572. DOI: 10.1016/j.ygyno.2020.09.002. View

Tentler J, Tan A, Weekes C, Jimeno A, Leong S, Pitts T . Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338-50. PMC: 3928688. DOI: 10.1038/nrclinonc.2012.61. View

Matte I, Legault C, Garde-Granger P, Laplante C, Bessette P, Rancourt C . Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clin Exp Metastasis. 2016; 33(8):839-852. DOI: 10.1007/s10585-016-9821-y. View

Sloan Stakleff K, Rouse A, RYAN A, Haller N, von Gruenigen V . A novel early-stage orthotopic model for ovarian cancer in the Fischer 344 rat. Int J Gynecol Cancer. 2005; 15(2):246-54. DOI: 10.1111/j.1525-1438.2005.15211.x. View

Kenny H, Lengyel E . MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009; 8(5):683-8. PMC: 2840625. DOI: 10.4161/cc.8.5.7703. View

Heredia-Soto V, Redondo A, Berjon A, Miguel-Martin M, Diaz E, Crespo R . High-throughput 3-dimensional culture of epithelial ovarian cancer cells as preclinical model of disease. Oncotarget. 2018; 9(31):21893-21903. PMC: 5955171. DOI: 10.18632/oncotarget.25098. View

10.

Frankel A, Buckman R, Kerbel R . Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Res. 1997; 57(12):2388-93. View

11.

Kapalczynska M, Kolenda T, Przybyla W, Zajaczkowska M, Teresiak A, Filas V . 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2018; 14(4):910-919. PMC: 6040128. DOI: 10.5114/aoms.2016.63743. View

12.

Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan D, Poggi A . The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci. 2020; 21(9). PMC: 7247443. DOI: 10.3390/ijms21093125. View

13.

Magnotti E, Marasco W . The latest animal models of ovarian cancer for novel drug discovery. Expert Opin Drug Discov. 2018; 13(3):249-257. PMC: 6487846. DOI: 10.1080/17460441.2018.1426567. View

14.

Trinidad C, Tetlow A, Bantis L, Godwin A . Reducing Ovarian Cancer Mortality Through Early Detection: Approaches Using Circulating Biomarkers. Cancer Prev Res (Phila). 2020; 13(3):241-252. PMC: 7080297. DOI: 10.1158/1940-6207.CAPR-19-0184. View

15.

Fang Y, Eglen R . Three-Dimensional Cell Cultures in Drug Discovery and Development. SLAS Discov. 2017; 22(5):456-472. PMC: 5448717. DOI: 10.1177/1087057117696795. View

16.

De Jaeghere E, De Vlieghere E, Van Hoorick J, Van Vlierberghe S, Wagemans G, Pieters L . Heterocellular 3D scaffolds as biomimetic to recapitulate the tumor microenvironment of peritoneal metastases in vitro and in vivo. Biomaterials. 2018; 158:95-105. DOI: 10.1016/j.biomaterials.2017.12.017. View

17.

Roby K, TAYLOR C, Sweetwood J, Cheng Y, Pace J, Tawfik O . Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000; 21(4):585-91. DOI: 10.1093/carcin/21.4.585. View

18.

Zheng L, Hu X, Huang Y, Xu G, Yang J, Li L . In vivo bioengineered ovarian tumors based on collagen, matrigel, alginate and agarose hydrogels: a comparative study. Biomed Mater. 2015; 10(1):015016. DOI: 10.1088/1748-6041/10/1/015016. View

19.

Wan X, Ball S, Willenbrock F, Yeh S, Vlahov N, Koennig D . Perfused Three-dimensional Organotypic Culture of Human Cancer Cells for Therapeutic Evaluation. Sci Rep. 2017; 7(1):9408. PMC: 5573358. DOI: 10.1038/s41598-017-09686-0. View

20.

Kenny H, Krausz T, Yamada S, Lengyel E . Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007; 121(7):1463-72. DOI: 10.1002/ijc.22874. View